JP2012509281A - リナクロチドのα結晶形 - Google Patents

リナクロチドのα結晶形 Download PDF

Info

Publication number
JP2012509281A
JP2012509281A JP2011536620A JP2011536620A JP2012509281A JP 2012509281 A JP2012509281 A JP 2012509281A JP 2011536620 A JP2011536620 A JP 2011536620A JP 2011536620 A JP2011536620 A JP 2011536620A JP 2012509281 A JP2012509281 A JP 2012509281A
Authority
JP
Japan
Prior art keywords
linaclotide
ray powder
diffraction pattern
powder diffraction
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509281A5 (enExample
Inventor
リテシュ サンフビ，
アンドレアス グリル，
ラフル スラナ，
ハイティアン チュウ，
Original Assignee
アイロンウッド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイロンウッド ファーマシューティカルズ， インコーポレイテッド filed Critical アイロンウッド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012509281A publication Critical patent/JP2012509281A/ja
Publication of JP2012509281A5 publication Critical patent/JP2012509281A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011536620A 2008-11-19 2009-11-18 リナクロチドのα結晶形 Pending JP2012509281A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11615608P 2008-11-19 2008-11-19
US61/116,156 2008-11-19
PCT/US2009/065001 WO2010059733A1 (en) 2008-11-19 2009-11-18 Crystalline form of linaclotide

Publications (2)

Publication Number Publication Date
JP2012509281A true JP2012509281A (ja) 2012-04-19
JP2012509281A5 JP2012509281A5 (enExample) 2013-01-10

Family

ID=42172504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536620A Pending JP2012509281A (ja) 2008-11-19 2009-11-18 リナクロチドのα結晶形

Country Status (6)

Country Link
US (3) US8222201B2 (enExample)
EP (1) EP2365821A4 (enExample)
JP (1) JP2012509281A (enExample)
CA (1) CA2743172A1 (enExample)
MX (1) MX2011005245A (enExample)
WO (1) WO2010059733A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502978A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体
JP2012502979A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011005245A (es) * 2008-11-19 2011-06-17 Forest Lab Holdings Ltd Forma cristalina de linaclotida.
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
WO2014118180A1 (en) 2013-01-30 2014-08-07 Sandoz Ag Crystalline form of linaclotide
CN104844693B (zh) * 2015-06-10 2018-08-03 成都圣诺生物科技股份有限公司 一种合成利那洛肽的方法
WO2017004510A2 (en) 2015-07-01 2017-01-05 Novetide Ltd. Solid state forms of linaclotide
CN107163105B (zh) * 2017-06-28 2020-12-11 清华大学 一种天然利那洛肽的结晶方法
EP4194464A1 (en) * 2021-12-13 2023-06-14 Chemi SPA Manufacturing process for the production of linaclotide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371271B2 (en) * 2001-04-02 2008-05-13 Mitsubishi Materials Pmg Corporation Composite soft magnetic sintered material having high density and high magnetic permeability and method for preparation thereof
BRPI0407071B8 (pt) 2003-01-28 2021-05-25 Ironwood Pharmaceuticals Inc peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
ES2391974T3 (es) 2003-06-13 2012-12-03 Ironwood Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de trastornos gastrointestinales
US20070010543A1 (en) 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
EP2671584A3 (en) 2007-05-04 2014-03-26 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
MX2011005245A (es) * 2008-11-19 2011-06-17 Forest Lab Holdings Ltd Forma cristalina de linaclotida.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502978A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体
JP2012502979A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体

Also Published As

Publication number Publication date
EP2365821A4 (en) 2013-09-04
US20120309695A1 (en) 2012-12-06
EP2365821A1 (en) 2011-09-21
US20120214750A1 (en) 2012-08-23
US8222201B2 (en) 2012-07-17
CA2743172A1 (en) 2010-05-27
US8293704B2 (en) 2012-10-23
WO2010059733A1 (en) 2010-05-27
US20100125056A1 (en) 2010-05-20
MX2011005245A (es) 2011-06-17

Similar Documents

Publication Publication Date Title
US8293704B2 (en) Crystalline form of linaclotide
JP7190612B2 (ja) 置換ピペリジン化合物及びその用途
JP6821701B2 (ja) Ｎ−［２−（３−ヒドロキシ−３−メチルブチル）−６−（２−ヒドロキシプロパン−２−イル）−２ｈ−インダゾール−５−イル］−６−（トリフルオロメチル）ピリジン−２−カルボキサミドの結晶形態
JP2010507565A (ja) メタスチン誘導体およびその用途
CN116615426A (zh) Fgfr抑制剂和其制造和使用方法
CN116768861A (zh) Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途
WO2018165575A2 (en) Warhead-containing peptidomimetic macrocycles as modulators of bfl-1
US9259403B2 (en) Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
TW201733992A (zh) 製備經取代５，６－二氫－６－苯基苯并［ｆ］異喹啉－２－胺之方法
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
TW200911757A (en) Crystalline forms of histone deacetylase inhibitors
US20250051322A1 (en) Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
EP4027993A1 (en) Cyclooxygenase-2 inhibitors and uses thereof
US12030886B2 (en) Form of ponatinib
CN115297856A (zh) 用于治疗糖尿病性视网膜病变的分拣蛋白拮抗剂
KR102890565B1 (ko) 2-(3,5-디클로로-4-((5-이소프로필-6-옥소-1,6-디히드로피리다진-3-일)옥시)페닐)-3,5-디옥소-2,3,4,5-테트라히드로-1,2,4-트리아진-6-카르보니트릴의 고체 형태
US20210395232A1 (en) Co-crystal forms of selinexor
US20220315558A1 (en) Polymorphs of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
HK40083601A (en) Substituted piperidine compound and application thereof
KR20210027454A (ko) 2-(3,5-디클로로-4-((5-이소프로필-6-옥소-1,6-디히드로피리다진-3-일)옥시)페닐)-3,5-디옥소-2,3,4,5-테트라히드로-1,2,4-트리아진-6-카르보니트릴의 고체 형태
KR20250167140A (ko) 2-(3,5-디클로로-4-((5-이소프로필-6-옥소-1,6-디히드로피리다진-3-일)옥시)페닐)-3,5-디옥소-2,3,4,5-테트라히드로-1,2,4-트리아진-6-카르보니트릴의고체 형태

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141029